Radiation Therapy Gets Personal: Diagnostic Tools Offer New Possibilities
This article was originally published in The Gray Sheet
Executive Summary
Radiation therapy that tailors treatment to individual tumor characteristics is advancing, with both the market leader in radiation devices and a small start-up firm eyeing business opportunities
You may also be interested in...
Diagnostics In Brief
BioNanomatrix, NCI collaborate: Genome imaging and analytic platform developer BioNanomatrix inks a multi-year research and development agreement with the National Cancer Institute, firm announces Jan. 18. The company will work with NCI's Radiation Biology Branch to develop tools to detect and quantify DNA damage caused by cancer therapies in order to optimize radiation dosing. BioNanomatrix's Nanoanalyzer whole genome analyzer unwinds DNA from its supercoiled structure to enable the identification of specific DNA aberrations. Pending successful results assessing radiation-induced damage, the firm plans to study DNA aberrations resulting from chemotherapy. BioNanomatrix has an exclusive license to use the technologies from Princeton University...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.